In assessing UMCD6 as a new candidate cancer immunotherapy agent, its consistently superior stimulation of cancer killing by lymphocytes in vitro, compared with either pembrolizumab or nivolumab, is notable but will need confirmation in vivo, and use of cells from patients with cancer, which may express higher levels of PD-1 than cells from healthy subjects. The gene discussed is PDCD1; the disease is cancer.